ID   MYSM1_HUMAN             Reviewed;         828 AA.
AC   Q5VVJ2; A8KA54; B3KX65; Q68DD3; Q6AI53; Q7Z3G8; Q96PX3;
DT   02-MAY-2006, integrated into UniProtKB/Swiss-Prot.
DT   07-DEC-2004, sequence version 1.
DT   28-JUN-2023, entry version 177.
DE   RecName: Full=Deubiquitinase MYSM1;
DE            Short=2A-DUB;
DE            EC=3.4.19.- {ECO:0000269|PubMed:33086059};
DE   AltName: Full=Myb-like, SWIRM and MPN domain-containing protein 1;
GN   Name=MYSM1; Synonyms=KIAA1915;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT ALA-264.
RC   TISSUE=Brain;
RX   PubMed=11572484; DOI=10.1093/dnares/8.4.179;
RA   Nagase T., Kikuno R., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XXI. The
RT   complete sequences of 60 new cDNA clones from brain which code for large
RT   proteins.";
RL   DNA Res. 8:179-187(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 144-828 (ISOFORM 1), AND VARIANT ALA-264.
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 1-133 (ISOFORM 1).
RC   TISSUE=Fetal skin, and Liver;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION IN COMPLEX, AND MUTAGENESIS
RP   OF ASP-669.
RX   PubMed=17707232; DOI=10.1016/j.molcel.2007.07.024;
RA   Zhu P., Zhou W., Wang J., Puc J., Ohgi K.A., Erdjument-Bromage H.,
RA   Tempst P., Glass C.K., Rosenfeld M.G.;
RT   "A histone H2A deubiquitinase complex coordinating histone acetylation and
RT   H1 dissociation in transcriptional regulation.";
RL   Mol. Cell 27:609-621(2007).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-218, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-218, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-218 AND THR-236, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [9]
RP   FUNCTION.
RX   PubMed=22169041; DOI=10.1016/j.immuni.2011.11.010;
RA   Jiang X.X., Nguyen Q., Chou Y., Wang T., Nandakumar V., Yates P., Jones L.,
RA   Wang L., Won H., Lee H.R., Jung J.U., Mueschen M., Huang X.F., Chen S.Y.;
RT   "Control of B cell development by the histone H2A deubiquitinase MYSM1.";
RL   Immunity 35:883-896(2011).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-340, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [11]
RP   INVOLVEMENT IN BMFS4, AND VARIANT BMFS4 390-GLU--MET-828 DEL.
RX   PubMed=24288411; DOI=10.1182/blood-2013-09-527127;
RA   Alsultan A., Shamseldin H.E., Osman M.E., Aljabri M., Alkuraya F.S.;
RT   "MYSM1 is mutated in a family with transient transfusion-dependent anemia,
RT   mild thrombocytopenia, and low NK- and B-cell counts.";
RL   Blood 122:3844-3845(2013).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH NFIL3.
RX   PubMed=24062447; DOI=10.1073/pnas.1308888110;
RA   Nandakumar V., Chou Y., Zang L., Huang X.F., Chen S.Y.;
RT   "Epigenetic control of natural killer cell maturation by histone H2A
RT   deubiquitinase, MYSM1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:E3927-E3936(2013).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-110; SER-218; SER-242 AND
RP   SER-267, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   FUNCTION, INVOLVEMENT IN BMFS4, AND VARIANT BMFS4 ARG-656.
RX   PubMed=26220525; DOI=10.1016/j.jaci.2015.06.008;
RA   Le Guen T., Touzot F., Andre-Schmutz I., Lagresle-Peyrou C., France B.,
RA   Kermasson L., Lambert N., Picard C., Nitschke P., Carpentier W.,
RA   Bole-Feysot C., Lim A., Cavazzana M., Callebaut I., Soulier J., Jabado N.,
RA   Fischer A., de Villartay J.P., Revy P.;
RT   "An in vivo genetic reversion highlights the crucial role of Myb-Like,
RT   SWIRM, and MPN domains 1 (MYSM1) in human hematopoiesis and lymphocyte
RT   differentiation.";
RL   J. Allergy Clin. Immunol. 136:1619-1626(2015).
RN   [15]
RP   FUNCTION, INVOLVEMENT IN BMFS4, AND VARIANT BMFS4 390-GLU--MET-828 DEL.
RX   PubMed=28115216; DOI=10.1016/j.jaci.2016.10.053;
RA   Bahrami E., Witzel M., Racek T., Puchalka J., Hollizeck S.,
RA   Greif-Kohistani N., Kotlarz D., Horny H.P., Feederle R., Schmidt H.,
RA   Sherkat R., Steinemann D., Goehring G., Schlegelbeger B., Albert M.H.,
RA   Al-Herz W., Klein C.;
RT   "Myb-like, SWIRM, and MPN domains 1 (MYSM1) deficiency: Genotoxic stress-
RT   associated bone marrow failure and developmental aberrations.";
RL   J. Allergy Clin. Immunol. 140:1112-1119(2017).
RN   [16]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-187, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [17]
RP   FUNCTION, INDUCTION BY INTRACELLULAR DNA, AND CATALYTIC ACTIVITY.
RX   PubMed=33086059; DOI=10.1016/j.celrep.2020.108297;
RA   Tian M., Liu W., Zhang Q., Huang Y., Li W., Wang W., Zhao P., Huang S.,
RA   Song Y., Shereen M.A., Qin M., Liu Y., Wu K., Wu J.;
RT   "MYSM1 Represses Innate Immunity and Autoimmunity through Suppressing the
RT   cGAS-STING Pathway.";
RL   Cell Rep. 33:108297-108297(2020).
RN   [18]
RP   STRUCTURE BY NMR OF 117-181 AND OF 367-470, AND INTERACTION WITH DNA.
RX   PubMed=17428495; DOI=10.1016/j.jmb.2007.03.027;
RA   Yoneyama M., Tochio N., Umehara T., Koshiba S., Inoue M., Yabuki T.,
RA   Aoki M., Seki E., Matsuda T., Watanabe S., Tomo Y., Nishimura Y.,
RA   Harada T., Terada T., Shirouzu M., Hayashizaki Y., Ohara O., Tanaka A.,
RA   Kigawa T., Yokoyama S.;
RT   "Structural and functional differences of SWIRM domain subtypes.";
RL   J. Mol. Biol. 369:222-238(2007).
CC   -!- FUNCTION: Metalloprotease with deubiquitinase activity that plays
CC       important regulator roles in hematopoietic stem cell function, blood
CC       cell production and immune response (PubMed:24062447, PubMed:26220525,
CC       PubMed:28115216). Participates in the normal programming of B-cell
CC       responses to antigen after the maturation process (By similarity).
CC       Within the cytoplasm, plays critical roles in the repression of innate
CC       immunity and autoimmunity (PubMed:33086059). Removes 'Lys-63'-linked
CC       polyubiquitins from TRAF3 and TRAF6 complexes (By similarity).
CC       Attenuates NOD2-mediated inflammation and tissue injury by promoting
CC       'Lys-63'-linked deubiquitination of RIPK2 component (By similarity).
CC       Suppresses the CGAS-STING1 signaling pathway by cleaving STING1 'Lys-
CC       63'-linked ubiquitin chains (PubMed:33086059). In the nucleus, acts as
CC       a hematopoietic transcription regulator derepressing a range of genes
CC       essential for normal stem cell differentiation including EBF1 and PAX5
CC       in B-cells, ID2 in NK-cell progenitor or FLT3 in dendritic cell
CC       precursors (PubMed:24062447). Deubiquitinates monoubiquitinated histone
CC       H2A, a specific tag for epigenetic transcriptional repression, leading
CC       to dissociation of histone H1 from the nucleosome (PubMed:17707232).
CC       {ECO:0000250|UniProtKB:Q69Z66, ECO:0000269|PubMed:17707232,
CC       ECO:0000269|PubMed:22169041, ECO:0000269|PubMed:24062447,
CC       ECO:0000269|PubMed:26220525, ECO:0000269|PubMed:28115216,
CC       ECO:0000269|PubMed:33086059}.
CC   -!- SUBUNIT: Component of a large chromatin remodeling complex, at least
CC       composed of MYSM1, PCAF, RBM10 and KIF11/TRIP5. Binds histones
CC       (PubMed:17707232). Interacts with NFIL3; this interaction is critical
CC       for their correct recruitment to the ID2 locus during natural killer
CC       cell maturation (PubMed:24062447). {ECO:0000269|PubMed:17707232,
CC       ECO:0000269|PubMed:24062447}.
CC   -!- INTERACTION:
CC       Q5VVJ2; Q5T2T1: MPP7; NbExp=3; IntAct=EBI-12262412, EBI-2514004;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00624,
CC       ECO:0000269|PubMed:17707232}. Cytoplasm {ECO:0000250|UniProtKB:Q69Z66}.
CC       Note=Localizes to the cytoplasm in response to bacterial infection.
CC       {ECO:0000250|UniProtKB:Q69Z66}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q5VVJ2-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q5VVJ2-2; Sequence=VSP_018211;
CC       Name=3;
CC         IsoId=Q5VVJ2-3; Sequence=VSP_018210;
CC   -!- INDUCTION: By DNA from viral infection and intracellular DNA.
CC       {ECO:0000269|PubMed:33086059}.
CC   -!- DOMAIN: Contains an N-terminal SANT domain that mediates histone/DNA
CC       binding, a central SWIRM domain to mediate interaction with chromatin
CC       associated proteins, and a C-terminal MPN domain that contains the
CC       metalloprotease activity. {ECO:0000269|PubMed:17707232}.
CC   -!- DISEASE: Bone marrow failure syndrome 4 (BMFS4) [MIM:618116]: A form of
CC       bone marrow failure syndrome, a heterogeneous group of life-threatening
CC       disorders characterized by hematopoietic defects in association with a
CC       range of variable extra-hematopoietic manifestations. BMFS4 is
CC       characterized by early-onset anemia, leukopenia, decreased B cells, and
CC       developmental aberrations including facial dysmorphism, mild skeletal
CC       anomalies, and neurodevelopmental delay. BMFS4 inheritance is autosomal
CC       recessive. {ECO:0000269|PubMed:24288411, ECO:0000269|PubMed:26220525,
CC       ECO:0000269|PubMed:28115216}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the peptidase M67A family. MYSM1 subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB67808.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAG54377.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB067502; BAB67808.1; ALT_INIT; mRNA.
DR   EMBL; AK126835; BAG54377.1; ALT_INIT; mRNA.
DR   EMBL; AK292919; BAF85608.1; -; mRNA.
DR   EMBL; BX537912; CAD97896.1; -; mRNA.
DR   EMBL; CR627323; CAH10370.1; -; mRNA.
DR   EMBL; CR749450; CAH18287.1; -; mRNA.
DR   EMBL; AL035411; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL450024; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS41343.1; -. [Q5VVJ2-1]
DR   RefSeq; NP_001078956.1; NM_001085487.2. [Q5VVJ2-1]
DR   RefSeq; XP_016855684.1; XM_017000195.1.
DR   RefSeq; XP_016855685.1; XM_017000196.1.
DR   RefSeq; XP_016855686.1; XM_017000197.1.
DR   PDB; 2CU7; NMR; -; A=117-181.
DR   PDB; 2DCE; NMR; -; A=367-470.
DR   PDBsum; 2CU7; -.
DR   PDBsum; 2DCE; -.
DR   AlphaFoldDB; Q5VVJ2; -.
DR   BMRB; Q5VVJ2; -.
DR   SMR; Q5VVJ2; -.
DR   BioGRID; 125363; 47.
DR   CORUM; Q5VVJ2; -.
DR   DIP; DIP-58941N; -.
DR   IntAct; Q5VVJ2; 4.
DR   STRING; 9606.ENSP00000418734; -.
DR   MEROPS; M67.005; -.
DR   GlyGen; Q5VVJ2; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q5VVJ2; -.
DR   PhosphoSitePlus; Q5VVJ2; -.
DR   BioMuta; MYSM1; -.
DR   DMDM; 74756898; -.
DR   EPD; Q5VVJ2; -.
DR   jPOST; Q5VVJ2; -.
DR   MassIVE; Q5VVJ2; -.
DR   MaxQB; Q5VVJ2; -.
DR   PaxDb; Q5VVJ2; -.
DR   PeptideAtlas; Q5VVJ2; -.
DR   ProteomicsDB; 65467; -. [Q5VVJ2-1]
DR   ProteomicsDB; 65468; -. [Q5VVJ2-2]
DR   ProteomicsDB; 65469; -. [Q5VVJ2-3]
DR   Antibodypedia; 46901; 297 antibodies from 30 providers.
DR   DNASU; 114803; -.
DR   Ensembl; ENST00000472487.6; ENSP00000418734.1; ENSG00000162601.12. [Q5VVJ2-1]
DR   GeneID; 114803; -.
DR   KEGG; hsa:114803; -.
DR   MANE-Select; ENST00000472487.6; ENSP00000418734.1; NM_001085487.3; NP_001078956.1.
DR   UCSC; uc001cza.4; human. [Q5VVJ2-1]
DR   AGR; HGNC:29401; -.
DR   CTD; 114803; -.
DR   DisGeNET; 114803; -.
DR   GeneCards; MYSM1; -.
DR   HGNC; HGNC:29401; MYSM1.
DR   HPA; ENSG00000162601; Low tissue specificity.
DR   MalaCards; MYSM1; -.
DR   MIM; 612176; gene.
DR   MIM; 618116; phenotype.
DR   neXtProt; NX_Q5VVJ2; -.
DR   OpenTargets; ENSG00000162601; -.
DR   Orphanet; 508542; Congenital progressive bone marrow failure-B-cell immunodeficiency-skeletal dysplasia syndrome.
DR   PharmGKB; PA142671301; -.
DR   VEuPathDB; HostDB:ENSG00000162601; -.
DR   eggNOG; KOG1279; Eukaryota.
DR   eggNOG; KOG1555; Eukaryota.
DR   GeneTree; ENSGT00940000157721; -.
DR   HOGENOM; CLU_018854_0_0_1; -.
DR   InParanoid; Q5VVJ2; -.
DR   OMA; FQSDFIA; -.
DR   OrthoDB; 2786778at2759; -.
DR   PhylomeDB; Q5VVJ2; -.
DR   TreeFam; TF324811; -.
DR   PathwayCommons; Q5VVJ2; -.
DR   Reactome; R-HSA-5689901; Metalloprotease DUBs.
DR   SignaLink; Q5VVJ2; -.
DR   BioGRID-ORCS; 114803; 33 hits in 1221 CRISPR screens.
DR   ChiTaRS; MYSM1; human.
DR   EvolutionaryTrace; Q5VVJ2; -.
DR   GenomeRNAi; 114803; -.
DR   Pharos; Q5VVJ2; Tbio.
DR   PRO; PR:Q5VVJ2; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q5VVJ2; protein.
DR   Bgee; ENSG00000162601; Expressed in calcaneal tendon and 172 other tissues.
DR   ExpressionAtlas; Q5VVJ2; baseline and differential.
DR   Genevisible; Q5VVJ2; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IPI:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0140950; F:histone H2A deubiquitinase activity; IMP:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0140492; F:metal-dependent deubiquitinase activity; IDA:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; IMP:UniProtKB.
DR   GO; GO:0002376; P:immune system process; IEA:UniProtKB-KW.
DR   GO; GO:0043473; P:pigmentation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:UniProtKB.
DR   GO; GO:0006508; P:proteolysis; IEA:UniProtKB-KW.
DR   GO; GO:0030334; P:regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0051797; P:regulation of hair follicle development; IEA:Ensembl.
DR   GO; GO:1903706; P:regulation of hemopoiesis; IMP:UniProtKB.
DR   CDD; cd08067; MPN_2A_DUB; 1.
DR   CDD; cd00167; SANT; 1.
DR   Gene3D; 3.40.140.10; Cytidine Deaminase, domain 2; 1.
DR   Gene3D; 1.10.10.60; Homeodomain-like; 1.
DR   Gene3D; 1.10.10.10; Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain; 1.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR000555; JAMM/MPN+_dom.
DR   InterPro; IPR037518; MPN.
DR   InterPro; IPR017930; Myb_dom.
DR   InterPro; IPR001005; SANT/Myb.
DR   InterPro; IPR017884; SANT_dom.
DR   InterPro; IPR007526; SWIRM.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   PANTHER; PTHR10410:SF39; DOMAIN-CONTAINING PROTEIN, PUTATIVE-RELATED; 1.
DR   PANTHER; PTHR10410; EUKARYOTIC TRANSLATION INITIATION FACTOR 3 -RELATED; 1.
DR   Pfam; PF01398; JAB; 1.
DR   Pfam; PF00249; Myb_DNA-binding; 1.
DR   Pfam; PF04433; SWIRM; 1.
DR   SMART; SM00232; JAB_MPN; 1.
DR   SMART; SM00717; SANT; 1.
DR   SUPFAM; SSF46689; Homeodomain-like; 2.
DR   SUPFAM; SSF102712; JAB1/MPN domain; 1.
DR   PROSITE; PS50249; MPN; 1.
DR   PROSITE; PS51293; SANT; 1.
DR   PROSITE; PS50934; SWIRM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Chromatin regulator;
KW   Cytoplasm; Disease variant; DNA-binding; Hydrolase; Immunity;
KW   Isopeptide bond; Metal-binding; Metalloprotease; Nucleus; Phosphoprotein;
KW   Protease; Reference proteome; Transcription; Transcription regulation;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc.
FT   CHAIN           1..828
FT                   /note="Deubiquitinase MYSM1"
FT                   /id="PRO_0000234073"
FT   DOMAIN          116..167
FT                   /note="SANT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00624"
FT   DOMAIN          372..470
FT                   /note="SWIRM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00247"
FT   DOMAIN          577..709
FT                   /note="MPN"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01182"
FT   REGION          1..31
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           656..669
FT                   /note="JAMM motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01182"
FT   MOTIF           774..778
FT                   /note="LXXLL motif"
FT   BINDING         656
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01182"
FT   BINDING         658
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01182"
FT   BINDING         669
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01182"
FT   MOD_RES         110
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         218
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         236
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         242
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         267
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         340
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   CROSSLNK        187
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..594
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:17974005"
FT                   /id="VSP_018210"
FT   VAR_SEQ         1..253
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11572484"
FT                   /id="VSP_018211"
FT   VARIANT         200
FT                   /note="C -> S (in dbSNP:rs17118103)"
FT                   /id="VAR_051814"
FT   VARIANT         264
FT                   /note="T -> A (in dbSNP:rs12139511)"
FT                   /evidence="ECO:0000269|PubMed:11572484,
FT                   ECO:0000269|PubMed:14702039"
FT                   /id="VAR_051815"
FT   VARIANT         390..828
FT                   /note="Missing (in BMFS4)"
FT                   /evidence="ECO:0000269|PubMed:24288411,
FT                   ECO:0000269|PubMed:28115216"
FT                   /id="VAR_081184"
FT   VARIANT         656
FT                   /note="H -> R (in BMFS4; dbSNP:rs1557507208)"
FT                   /evidence="ECO:0000269|PubMed:26220525"
FT                   /id="VAR_081185"
FT   VARIANT         825
FT                   /note="E -> K (in dbSNP:rs232777)"
FT                   /id="VAR_051816"
FT   MUTAGEN         669
FT                   /note="D->N: Abolishes H2A deubiquitination."
FT                   /evidence="ECO:0000269|PubMed:17707232"
FT   CONFLICT        231
FT                   /note="E -> G (in Ref. 2; BAG54377)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        540
FT                   /note="G -> D (in Ref. 2; BAG54377)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        782
FT                   /note="R -> G (in Ref. 3; CAH18287)"
FT                   /evidence="ECO:0000305"
FT   HELIX           123..135
FT                   /evidence="ECO:0007829|PDB:2CU7"
FT   HELIX           140..147
FT                   /evidence="ECO:0007829|PDB:2CU7"
FT   STRAND          148..150
FT                   /evidence="ECO:0007829|PDB:2CU7"
FT   HELIX           152..166
FT                   /evidence="ECO:0007829|PDB:2CU7"
FT   HELIX           388..391
FT                   /evidence="ECO:0007829|PDB:2DCE"
FT   HELIX           395..398
FT                   /evidence="ECO:0007829|PDB:2DCE"
FT   HELIX           406..423
FT                   /evidence="ECO:0007829|PDB:2DCE"
FT   HELIX           430..432
FT                   /evidence="ECO:0007829|PDB:2DCE"
FT   TURN            433..437
FT                   /evidence="ECO:0007829|PDB:2DCE"
FT   STRAND          438..441
FT                   /evidence="ECO:0007829|PDB:2DCE"
FT   HELIX           443..456
FT                   /evidence="ECO:0007829|PDB:2DCE"
FT   STRAND          457..460
FT                   /evidence="ECO:0007829|PDB:2DCE"
FT   STRAND          466..468
FT                   /evidence="ECO:0007829|PDB:2DCE"
SQ   SEQUENCE   828 AA;  95032 MW;  9EE635A30AF3B089 CRC64;
     MAAEEADVDI EGDVVAAAGA QPGSGENTAS VLQKDHYLDS SWRTENGLIP WTLDNTISEE
     NRAVIEKMLL EEEYYLSKKS QPEKVWLDQK EDDKKYMKSL QKTAKIMVHS PTKPASYSVK
     WTIEEKELFE QGLAKFGRRW TKISKLIGSR TVLQVKSYAR QYFKNKVKCG LDKETPNQKT
     GHNLQVKNED KGTKAWTPSC LRGRADPNLN AVKIEKLSDD EEVDITDEVD ELSSQTPQKN
     SSSDLLLDFP NSKMHETNQG EFITSDSQEA LFSKSSRGCL QNEKQDETLS SSEITLWTEK
     QSNGDKKSIE LNDQKFNELI KNCNKHDGRG IIVDARQLPS PEPCEIQKNL NDNEMLFHSC
     QMVEESHEEE ELKPPEQEIE IDRNIIQEEE KQAIPEFFEG RQAKTPERYL KIRNYILDQW
     EICKPKYLNK TSVRPGLKNC GDVNCIGRIH TYLELIGAIN FGCEQAVYNR PQTVDKVRIR
     DRKDAVEAYQ LAQRLQSMRT RRRRVRDPWG NWCDAKDLEG QTFEHLSAEE LAKRREEEKG
     RPVKSLKVPR PTKSSFDPFQ LIPCNFFSEE KQEPFQVKVA SEALLIMDLH AHVSMAEVIG
     LLGGRYSEVD KVVEVCAAEP CNSLSTGLQC EMDPVSQTQA SETLAVRGFS VIGWYHSHPA
     FDPNPSLRDI DTQAKYQSYF SRGGAKFIGM IVSPYNRNNP LPYSQITCLV ISEEISPDGS
     YRLPYKFEVQ QMLEEPQWGL VFEKTRWIIE KYRLSHSSVP MDKIFRRDSD LTCLQKLLEC
     MRKTLSKVTN CFMAEEFLTE IENLFLSNYK SNQENGVTEE NCTKELLM
//
